IL33072A - תכשירים המכילים דופא וחומצה א- הידראזינו-3,4- גיניגאטורביפמילפאופיונית להגדלת תכולת הדופאמין ברקמת המוח של בעלי חיים - Google Patents
תכשירים המכילים דופא וחומצה א- הידראזינו-3,4- גיניגאטורביפמילפאופיונית להגדלת תכולת הדופאמין ברקמת המוח של בעלי חייםInfo
- Publication number
- IL33072A IL33072A IL33072A IL3307269A IL33072A IL 33072 A IL33072 A IL 33072A IL 33072 A IL33072 A IL 33072A IL 3307269 A IL3307269 A IL 3307269A IL 33072 A IL33072 A IL 33072A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- composition according
- dopa
- hydrazino
- brain tissue
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims description 40
- 229960003638 dopamine Drugs 0.000 title claims description 20
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims description 15
- 210000005013 brain tissue Anatomy 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title claims 11
- 241001465754 Metazoa Species 0.000 title description 7
- IPHPUCLNGNPXOU-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-2-hydrazinylpropanoic acid Chemical compound NNC(C)(C(O)=O)C1=CC=C(O)C(O)=C1 IPHPUCLNGNPXOU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 8
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 7
- -1 hydrazine compound Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010001541 Akinesia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- AKWHTKRUNUYXDS-UHFFFAOYSA-N Dihydroxyphenylpropionic acid Chemical compound OC(=O)CC(O)C1=CC=C(O)C=C1 AKWHTKRUNUYXDS-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001653 corpus striatum Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013114 circling movement Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76432568A | 1968-10-01 | 1968-10-01 | |
| US83573069A | 1969-06-23 | 1969-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL33072A0 IL33072A0 (en) | 1969-11-30 |
| IL33072A true IL33072A (he) | 1973-04-30 |
Family
ID=27117439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL33072A IL33072A (he) | 1968-10-01 | 1969-09-26 | תכשירים המכילים דופא וחומצה א- הידראזינו-3,4- גיניגאטורביפמילפאופיונית להגדלת תכולת הדופאמין ברקמת המוח של בעלי חיים |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE739625A (he) |
| CA (1) | CA957945A (he) |
| CY (1) | CY648A (he) |
| DE (1) | DE1949376C3 (he) |
| ES (1) | ES372009A1 (he) |
| FR (1) | FR2019605B1 (he) |
| GB (1) | GB1243474A (he) |
| IE (1) | IE33581B1 (he) |
| IL (1) | IL33072A (he) |
| NL (1) | NL149372B (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU464903B2 (en) * | 1970-11-12 | 1975-09-11 | Merck & Co., Inc | Treatment of hypertension |
| DE4101873C2 (de) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462536A (en) * | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
-
1969
- 1969-09-18 NL NL696914185A patent/NL149372B/xx not_active IP Right Cessation
- 1969-09-23 IE IE1326/69A patent/IE33581B1/xx unknown
- 1969-09-26 CA CA063,304A patent/CA957945A/en not_active Expired
- 1969-09-26 IL IL33072A patent/IL33072A/he unknown
- 1969-09-29 ES ES372009A patent/ES372009A1/es not_active Expired
- 1969-09-29 GB GB47811/69A patent/GB1243474A/en not_active Expired
- 1969-09-30 BE BE739625D patent/BE739625A/xx not_active IP Right Cessation
- 1969-09-30 DE DE1949376A patent/DE1949376C3/de not_active Expired
- 1969-10-01 FR FR696933459A patent/FR2019605B1/fr not_active Expired
-
1972
- 1972-07-04 CY CY64872A patent/CY648A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL33072A0 (en) | 1969-11-30 |
| FR2019605B1 (he) | 1973-06-08 |
| IE33581L (en) | 1970-04-01 |
| GB1243474A (en) | 1971-08-18 |
| IE33581B1 (en) | 1974-08-21 |
| NL149372B (nl) | 1976-05-17 |
| DE1949376B2 (de) | 1977-10-06 |
| ES372009A1 (es) | 1972-05-01 |
| CA957945A (en) | 1974-11-19 |
| CY648A (en) | 1972-07-04 |
| FR2019605A1 (he) | 1970-07-03 |
| NL6914185A (he) | 1970-04-03 |
| BE739625A (he) | 1970-03-31 |
| DE1949376A1 (de) | 1970-06-18 |
| DE1949376C3 (de) | 1978-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3769424A (en) | Composition and method of treating dopamine deficiency in brain tissue | |
| US5158978A (en) | Thyroid hormone treatment of acute cardiovascular compromise | |
| Price | Effects of carbon dioxide on the cardiovascular system | |
| US5017607A (en) | Method to treat Parkinsons disease | |
| KR0173459B1 (ko) | 식욕감소를 위한 조성물 및 그 방법 | |
| KR840003414A (ko) | 3-히드록시부탄산 또는 이 산으로부터 유도된 염을 함유하는 약학적 조성물과, 의약품으로 사용할 수 있는 3-히드록시부탄산으로부터 유도된 화합물 | |
| Heyma et al. | D-propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine. | |
| US4590213A (en) | Anti-anxiety method | |
| Rinne et al. | Plasma concentration of levodopa in patients with Parkinson’s disease: response to administration of levodopa alone or combined with a decarboxylase inhibitor and clinical correlations | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| EP0466909B1 (en) | Thyroid hormone for cardiac treatment | |
| CA2150417A1 (en) | Composition and method for the treatment of premenstrual syndrome | |
| US2761807A (en) | Glycocyamine and methylating agent in vivo creatine producing composition | |
| US3439094A (en) | Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol | |
| IL33072A (he) | תכשירים המכילים דופא וחומצה א- הידראזינו-3,4- גיניגאטורביפמילפאופיונית להגדלת תכולת הדופאמין ברקמת המוח של בעלי חיים | |
| White et al. | Protection against experimental beryllium poisoning by aurin tricarboxylic acid | |
| PT78492B (en) | Process for the preparation of a pharmaceutical composition for controlling seizures specifically epilepsy | |
| US3995058A (en) | Treatment of ethanol withdrawal symptoms with levodopa | |
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| US3658968A (en) | Composition and method of treatment | |
| KARTZINEL et al. | Studies with bromocriptine Part 2. Double‐blind comparison with levodopa in idiopathic parkinsonism | |
| DE2750159A1 (de) | Infusionsloesung zur behandlung von hepatischer encephalopathie und ein verfahren zu deren herstellung | |
| JPH0152366B2 (he) | ||
| Davies et al. | The antituberculous activity of ethyl thiolesters with particular reference to diethyl dithiolisophthalate | |
| US3542929A (en) | Chemotherapeutic compositions useful in animal detoxification |